Type 2 Diabetes

Avandia may cut diabetes and CVD risk in blacks and Hispanics

Published in Drug Week, July 16th, 2004

New data presented at the 64th scientific sessions of the American Diabetes Association suggest that, in certain ethnic populations with, and predisposed to, type 2 diabetes, the insulin sensitizer Avandia (rosiglitazone maleate) may reduce the risk for developing diabetes and diabetes-related cardiovascular disease (CVD).

In one study, data suggest that Avandia may delay and prevent progression to type 2 diabetes and premature cardiovascular disease, specifically in African-American patients with impaired glucose tolerance (IGT), commonly referred to as prediabetes.

In a separate study of African-American and Hispanic-American patients with type 2...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2004-07-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry